SOLICITATION NOTICE
B -- Pooled Analysis of Prospective Cohort Studies: Associations between Sex Steroid Hormones and Adenocarcinomas of the Esophagus - Notice of Intent
- Notice Date
- 7/6/2015
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- NCI-N02CP52636-88
- Archive Date
- 8/5/2015
- Point of Contact
- Chad M. Shearer, Phone: 2402766801
- E-Mail Address
-
chad.shearer@nih.gov
(chad.shearer@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Notice of Intent National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics DCEG), Epidemiology and Biostatistics Program (EBP), Hormonal and Reproductive Epidemiology Branch (HREB) plans to procure on a sole source basis services related to the sampling, analysis, and data management of serum samples from the NCI Cohort Consortium including Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M3-C862, PO Box 19024, Seattle, WA 98109. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 621511 and the business size standard is $32.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance is twelve (12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. HREB's research mission is to focus on hormonal and reproductive cancers, and other malignancies with possible hormonal etiologies (e.g., liver, esophageal). The HREB focuses on high-quality, high-impact research on hormonally-related cancers and cancers of the reproductive system: breast, endometrium, ovary, cervix, prostate and testis. They also seek to understand the epidemiology of a number of other malignancies, some of which are hormonally influenced. These include cancers of the liver and bladder, and esophageal adenocarcinomas. Their research is predicated on rigorous epidemiologic approaches, with integration of state-of-the-art methods for defining exposures of interest. The proposed study will be the first prospective analysis of inflammation markers and esophageal adenocarcinoma. The NCI will apply state-of-the-art laboratory analyses to quantitate circulating concentrations of inflammation markers and assess whether these are associated with subsequent risk of esophageal adenocarcinoma. The Contractor shall: (1) Select all individuals with a first cancer diagnosis of esophageal adenocarcinoma (ICD-10: C150-159 with histology code ICD-O-3: 8140-8575) identified during follow-up that have at least 275 ul of pre-diagnostic serum available for analysis. (2) Use incidence-density sampling with replacement to match 1 control per case based on sex, race/ethnicity, date of birth (+/- 1 year), date of entry (+/- 1 year), exit date (>=date of diagnosis of index case and defined as diagnosis of cancer [exc. NMSC], death, loss to follow-up, or end of follow-up), and number of freeze-thaw cycles of serum available for analysis. (3) Aliquot 275 ul of serum for each case and each control unless part of a random 10% selection, in which case 395 ul will be aliquoted. (4) Ship the samples to NCI and provide an electronic manifest that identifies the case-control pairs as well as the random 10% that have the higher volume of serum (395 ul). (5) Provide demographic, clinical, and questionnaire data needed for the statistical analysis. (6) All biological materials provided by the U.S. Government and all data generated shall be the property of the U.S. Government. The NCI Cohort Consortium is an extramural-intramural partnership formed by the National Cancer Institute (NCI) to address the need for large-scale collaborations to pool the large quantity of data and biospecimens necessary to conduct a wide range of cancer studies. The Consortium, through its collaborative network of investigators, provides a coordinated, interdisciplinary approach to tackling important scientific questions, economies of scale, and opportunities to quicken the pace of research. Based on this information this is a unique source to fulfill this requirement. All studies within the NCI Cohort Consortium were contacted to identify if they met the needs of this requirement. All studies that affirmed their capability have been included in this project. The Women's Health Initiative located at Fred Hutchinson can provide samples from their concurrent research activities and thus ensures a continuity of information. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 8:00 AM EST, on July 21, 2015. All responses and questions must be in writing and faxed 240-276-5401or emailed to Chad Shearer, Contract Specialist, via electronic mail at chad.shearer@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration and the Online Representations and Certifications Applications through the system for Awards Management website (sam.gov). Reference: NCI- N02CP52636-88 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-N02CP52636-88/listing.html)
- Place of Performance
- Address: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 9609 Medical Center Drive, Rm 7-E106, MSC 9774, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03786789-W 20150708/150706235021-9fcdced69d18a15adff023d6bb22abef (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |